We are live on ! Find out more
PIP

Palisades Investment Partners Portfolio holdings

AUM $352M
1-Year Est. Return 76.79%
This Fund
S&P 500
This Quarter Est. Return
+25.11%
1 Year Est. Return
+76.79%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$229M
AUM Growth
+$29.5M
Cap. Flow
-$2.71M
Cap. Flow %
-1.19%
Top 10 Hldgs %
53.1%
Holding
42
New
2
Increased
4
Reduced
31
Closed
3

Top Buys

Rank Stock Value
1
ITRI icon
Itron
ITRI
+$8.32M
2
RELY icon
Remitly
RELY
+$3.67M
3
ENVA icon
Enova International
ENVA
+$2.3M
4
CRMD icon
CorMedix
CRMD
+$2.25M
5
DCTH icon
Delcath Systems
DCTH
+$1.38M

Sector Composition

Rank Sector Weight
1 Technology 29.2%
2 Industrials 27.33%
3 Healthcare 24.95%
4 Financials 10.88%
5 Consumer Discretionary 5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STRL icon
1
Sterling Infrastructure
STRL
$16.4B
$22.8M 9.96%
98,728
-20,072
-17% -$3.5M
INOD icon
2
Innodata
INOD
$2.27B
$18.9M 8.26%
368,852
-10,557
-3% -$417K
SPXC icon
3
SPX Corp
SPXC
$10.8B
$18.6M 8.14%
111,008
-1,141
-1% -$167K
MMYT icon
4
MakeMyTrip
MMYT
$5.76B
$11.4M 5%
116,723
-12,269
-10% -$1.24M
ITRI icon
5
Itron
ITRI
$4.62B
$9.68M 4.23%
+73,563
New +$8.32M
INTA icon
6
Intapp
INTA
$2.85B
$8.47M 3.7%
164,059
-4,783
-3% -$261K
UFPT icon
7
UFP Technologies
UFPT
$2.49B
$8.42M 3.68%
34,503
-973
-3% -$219K
BMI icon
8
Badger Meter
BMI
$4.04B
$8.25M 3.61%
33,669
-935
-3% -$212K
WGS icon
9
GeneDx Holdings
WGS
$2.08B
$7.66M 3.35%
82,975
-938
-1% -$73.6K
ADMA icon
10
ADMA Biologics
ADMA
$2.15B
$7.26M 3.17%
398,647
-11,799
-3% -$241K
CRMD icon
11
CorMedix
CRMD
$581M
$6.93M 3.03%
562,527
+203,557
+57% +$2.25M
SPSC icon
12
SPS Commerce
SPSC
$2.61B
$6.66M 2.91%
48,913
-1,440
-3% -$200K
PAY icon
13
Paymentus
PAY
$5.03B
$6.39M 2.79%
195,036
-2,619
-1% -$87.7K
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
$6.23M 2.72%
132,555
-3,923
-3% -$175K
ENVA icon
15
Enova International
ENVA
$6.55B
$6.08M 2.66%
54,475
+24,066
+79% +$2.3M
MWA icon
16
Mueller Water Products
MWA
$4.13B
$5.66M 2.47%
235,398
-2,048
-0.9% -$50.7K
KRYS icon
17
Krystal Biotech
KRYS
$9.64B
$5.53M 2.42%
40,203
-493
-1% -$72.4K
AMSC icon
18
American Superconductor
AMSC
$1.6B
$5.15M 2.25%
140,498
-4,106
-3% -$101K
MEDP icon
19
Medpace
MEDP
$16.4B
$4.95M 2.16%
15,757
-417
-3% -$125K
MC icon
20
Moelis & Co
MC
$5.14B
$4.74M 2.07%
76,002
-728
-0.9% -$40.9K
VCYT icon
21
Veracyte
VCYT
$3.71B
$4.39M 1.92%
162,408
-4,734
-3% -$137K
LUNR icon
22
Intuitive Machines
LUNR
$2.24B
$4.25M 1.86%
391,240
-10,522
-3% -$103K
DCTH icon
23
Delcath Systems
DCTH
$436M
$3.68M 1.61%
270,310
+99,226
+58% +$1.38M
FFBC icon
24
First Financial Bancorp
FFBC
$3.61B
$3.62M 1.58%
149,198
-3,933
-3% -$93.3K
FISI icon
25
Financial Institutions
FISI
$836M
$3.52M 1.54%
136,916
-1,231
-0.9% -$30.7K

Similar funds

Palisades Investment Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Palisades Investment Partners held 42 positions worth $229M, up 15% from $199M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Palisades Investment Partners's Q2 2025 filing shows 2 new, 4 increased, 31 reduced and 3 closed positions. Its largest new stake was Itron: 73,563 shares worth $9.68M. The largest sale was AeroVironment, an estimated $6.28M.

By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 27% a quarter earlier, followed by Industrials and Healthcare.

  • Palisades Investment Partners's largest Q2 2025 buy was Itron: 73,563 shares worth $9.68M.
  • Palisades Investment Partners added most to Enova International in Q2 2025, an estimated $2.3M increase.
  • Palisades Investment Partners's biggest Q2 2025 reduction was Camtek, cutting an estimated $3.95M.
  • Palisades Investment Partners fully exited AeroVironment in Q2 2025, selling an estimated $6.28M.
  • Palisades Investment Partners's ten largest holdings make up 53% of its $229M portfolio in Q2 2025.
  • Palisades Investment Partners opened 2 new positions and closed 3 in Q2 2025.
  • Palisades Investment Partners's portfolio value rose 15% quarter-over-quarter to $229M.

Based on Palisades Investment Partners's 13F filing for Q2 2025, filed 17 Jul 2025.